CareDx (CDNA) Projected to Post Earnings on Wednesday

CareDx (NASDAQ:CDNA) is projected to release its earnings data after the market closes on Wednesday, February 26th. Analysts expect CareDx to post earnings of $0.05 per share and revenue of $84.56 million for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

CareDx Stock Down 4.1 %

NASDAQ:CDNA opened at $21.37 on Tuesday. The firm’s fifty day simple moving average is $22.66 and its 200 day simple moving average is $25.36. The stock has a market cap of $1.15 billion, a P/E ratio of -7.91 and a beta of 1.87. CareDx has a twelve month low of $7.42 and a twelve month high of $34.84.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on CDNA. HC Wainwright reaffirmed a “neutral” rating and set a $26.00 target price on shares of CareDx in a research note on Tuesday, January 14th. StockNews.com cut CareDx from a “buy” rating to a “hold” rating in a research report on Tuesday, February 18th. Wells Fargo & Company raised CareDx from an “underweight” rating to an “equal weight” rating and decreased their target price for the stock from $28.00 to $24.00 in a research report on Wednesday, January 15th. Finally, BTIG Research dropped their price target on CareDx from $40.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.33.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.